Nicotinic acid,
does it really help with Mean LDL-C percentage change in primary hypercholesterolaemia?
research showsIn the FDA fixed-dose trial table, mean LDL-C changes were −14% with ER niacin 2000 mg/day and −1% with placebo, an arithmetic contrast of −13 percentage points. The label defines a 16-week period including four-week titration; this surrogate improvement is not reduced myocardial infarction or mortality. [S15; S16]
ads claimThis is not individual dosing advice. It does not establish the same effect for generic vitamin B3, no-flush niacin, nicotinamide or another formulation. [S15:form]
Four separate assessment dimensions
| Effect direction and size | In the FDA fixed-dose trial table, mean LDL-C changes were −14% with ER niacin 2000 mg/day and −1% with placebo, an arithmetic contrast of −13 percentage points. The label defines a 16-week period including four-week titration; this surrogate improvement is not reduced myocardial infarction or mortality. [S15; S16] |
|---|---|
| Evidence certainty | The current rubric caps surrogate endpoint S and EX(a) at C. Zero counted strengths gives the fixed 46-point anchor. This does not deny the lipid decrease; it avoids claiming established clinical importance, independent replication or verified precision. |
| Applicability | Primary hypercholesterolaemia with LDL-C >160 mg/dL despite diet; not nutrient-deficiency correction or the statin-add-on strategy. |
| Safety | Pharmacological-dose niacin carries flushing, liver-enzyme, glucose/urate and specific laboratory-interference concerns. Other immediate/sustained-release formulations are not assumed interchangeable milligram for milligram. Arm-specific safety denominators for the small pivotal trial were not confirmed; pooled FDA 2020 safety data were not labelled as that trial’s rates. Research doses are not personal dosing instructions. [S15:safety; S15:interference] |
C/46 is a Chamgap rule-based evidence indicator, not a treatment-success probability. Document quality A is separate, and precision/applicability limits remain explicit.
Useful facts when choosing a product
- The total 122-person trial also includes a 1000 mg arm; the key comparison uses baseline n=41 for 2000 mg and n=40 for placebo. [S15:ldl_table3; S16:design]
- Mean LDL-C changes are −14% versus −1%, giving an arithmetic contrast of −13 percentage points from concurrent Table 3 data. [S15:ldl_table3]
- P<0.05 is neither an exact P value nor a CI/SD. Table 5 medians/IQRs and unmatched Table 4 time points were not used to fill missing dispersion. [S15:ldl_table3; S15:table4_limit; S15:table5_limit]
Chamgap Semantic Classification Code
Permanent code issued
M.niaspan-er-nicotinic-acid.oral.ldl-cholesterol.reduce.placeboMedicines > NIASPAN extended-release nicotinic acid > Oral > LDL-C percentage change in primary hypercholesterolaemia > Reduction claim > Placebo
Technically bound to the ChatGPT-verified boundary of NIASPAN 2000 mg/day over 16 weeks including titration, primary hypercholesterolaemia, placebo comparison, and LDL-C percentage change. Other doses, formulations, and statin add-on strategies remain separate. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | M · Medicine |
|---|---|
| Canonical ingredient or intervention | Nicotinic acid (prescription NIASPAN extended-release tablets) |
| Source or part used | Nicotinic acid chemical entity; botanical part not applicable, manufacturing origin unconfirmed |
| Formulation or processing | NIASPAN nicotinic-acid extended-release tablets; not nicotinamide or inositol hexanicotinate |
| Route | Oral |
| Dose | Key contrast 2000 mg/day; the same trial’s 1000 mg/day arm is auxiliary, not pooled into an average dose |
| Duration | Label table: 16 weeks including four-week titration. Publisher abstract: 12 weeks of treatment; both source definitions are retained. |
| Population | Primary hypercholesterolaemia with LDL-C >160 mg/dL despite diet; not nutrient-deficiency correction or the statin-add-on strategy. |
| Effect or condition | Mean LDL-C percentage change in primary hypercholesterolaemia |
| Primary endpoint | Mean LDL-C percentage change at 16 weeks in label Table 3. The abstract is not treated as verification of an original registered primary endpoint. |
| Comparator | Matched placebo on the dietary-treatment background; concurrent fixed-dose 2000 mg contrast, not mixed with unmatched dose-escalation time points. |
| Duplicate-detection key | nicotinic-acid|NIASPAN-ER|oral|2000mg-day|primary-hypercholesterolemia-LDL-over160-despite-diet|LDL-mean-percent-change|16weeks-including-titration|diet-plus-placebo |
What the research actually shows
In the FDA fixed-dose trial table, mean LDL-C changes were −14% with ER niacin 2000 mg/day and −1% with placebo, an arithmetic contrast of −13 percentage points. The label defines a 16-week period including four-week titration; this surrogate improvement is not reduced myocardial infarction or mortality. The primary abstract agrees on −14% LDL-C at 2000 mg. Its 12 weeks and the label’s 16 weeks including titration remain source-specific; discrepancies in other dose/TG figures were not silently repaired. [S15:ldl_table3; S16:design; S16:ldl]
Why this is classified as C (46)
The current rubric caps surrogate endpoint S and EX(a) at C. Zero counted strengths gives the fixed 46-point anchor. This does not deny the lipid decrease; it avoids claiming established clinical importance, independent replication or verified precision.
Counterpoint. Some figures in the publisher abstract and regulatory summary differ at other doses/endpoints. Only the agreeing 2000 mg LDL result and explicitly labelled source time frames are used; the unexplained differences are not asserted to be rounding. [S15; S16]
Rejudgment record. Retains both the consistent lipid decrease and its interpretation limits — Provided rubric precedents 28, 29 and 40, surrogate cap, actual grade calculator, and C46 fixed anchor for zero strengths
| Endpoint | S | Surrogate marker - laboratory or imaging measures Case application: S: blood surrogate. |
| Replication | R1 | Single confirmatory trial Case application: R1: the identified trial family is not double-counted. Multiple label trials are not R2 without verified independent authors/funding. |
| Independence | I1 | Mixed funding sources |
| Effect size | EX | The clinical size of the effect could not be judged |
| Precision | CX | No pooled confidence interval could be confirmed Case application: CX: lipid contrast CI unconfirmed; no substitution of a cardiovascular HR CI. |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Review performed and remaining limitations
Baseline sample sizes were confirmed, but exact analysis/completion/loss denominators and missing-data methods remain unconfirmed because the full original paper was inaccessible. The complete funding/COI statements were inaccessible. Rubric precedent 29 assigns I1 with explicit uncertainty; neither exclusive manufacturer funding nor independence is asserted.
Preliminary RoB 2-informed review — not a complete formal assessment
| Randomization | Randomized double-blind design is verified in the abstract; implementation of allocation concealment and maintenance-of-masking checks were not accessible. |
|---|---|
| Deviations from assigned interventions | Dose and diet/placebo comparison verified; detailed adherence remains unconfirmed. |
| Missing outcome data | Baseline sample sizes were confirmed, but exact analysis/completion/loss denominators and missing-data methods remain unconfirmed because the full original paper was inaccessible. |
| Outcome measurement | Objective blood-lipid marker. Sample/time/%p distinctions are retained without turning it into event prevention. |
| Selection of the reported result | The 1996 primary abstract was compared with FDA Table 3. No claim is made to have read an original registry/protocol. |
Reasons for the certainty judgment — not formal GRADE
| Risk of bias | B1: identified pivotal trial n=122, below 200. |
|---|---|
| Inconsistency | Primary and regulatory figures crosschecked; discrepancies at other endpoints/times are neither hidden nor pooled. |
| Indirectness | No generalization to other formulations, populations, co-treatments or clinical events. |
| Imprecision | Lipid contrast CI/SD unconfirmed. The observed decrease is retained with EX(a), not relabelled null or below MCID. |
| Publication bias | Exhaustive database/unpublished-trial searching was not achieved; publication bias is not declared absent. |
Search scope and limitations. 2026-09-14 web-index discovery, the provided 3081-record index and relevant originals, and direct publisher/FDA/NHLBI sources. See verification report and sources.json for queries/access failures; not an exhaustive PubMed systematic search.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Morgan 1996 NIASPAN 122-person trial | Randomized double-blind fixed-dose placebo-controlled trial | 122 total; baseline n=41/40 for the key contrast; analysis n unconfirmed | The complete funding/COI statements were inaccessible. Rubric precedent 29 assigns I1 with explicit uncertainty; neither exclusive manufacturer funding nor independence is asserted. | Mean LDL-C percentage change at 16 weeks in label Table 3. The abstract is not treated as verification of an original registered primary endpoint. | In the FDA fixed-dose trial table, mean LDL-C changes were −14% with ER niacin 2000 mg/day and −1% with placebo, an arithmetic contrast of −13 percentage points. The label defines a 16-week period including four-week titration; this surrogate improvement is not reduced myocardial infarction or mortality. | Pivotal trial within the bounded question; crosschecked against S15 official clinical data |
Receipt — 2 References
Evidence access cutoff: 2026-09-14. Each citation states its actual access level (full-text transcription, abstract, index, or other) and remaining limitations. Bibliographic checking does not certify the study results or treatment efficacy.
Technical integration by: Codex · Evidence date: 2026-09-14 · Corrections: 5
Correction log — 5
Corrections applied to this verdict, in chronological order. Changes are logged, not erased.
- 2026-09-14 · Pre-submission self-check correction / prevented misreading — See shared/corrections.json; source IDs: S15,S17,S19 (grade not_published→C)
- 2026-09-14 · Pre-submission self-check correction / prevented misreading — See shared/corrections.json; source IDs: S15,S17 (grade not_published→C)
- 2026-09-14 · Pre-submission self-check correction / prevented misreading — See shared/corrections.json; source IDs: S15 (grade not_published→C)
- 2026-09-14 · Pre-submission self-check correction / prevented misreading — See shared/corrections.json; source IDs: L128,S15 (grade not_published→C)
- 2026-09-14 · Pre-submission self-check correction / prevented misreading — See shared/corrections.json; source IDs: S15,S16 (grade not_published→C)
Cite this verdict
[Chamgap] ER nicotinic acid × LDL-C in primary hypercholesterolaemia — Evidence Grade C·46. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/niaspan-primary-hypercholesterolemia-ldl/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.